Accessibility Menu
Puma Biotechnology Stock Quote

Puma Biotechnology (NASDAQ: PBYI)

$5.04
(-3.6%)
-0.19
Price as of October 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$5.04
Daily Change
(-3.6%) $0.19
Day's Range
$5 - $5.24
Previous Close
$5.04
Open
$5.23
Beta
1.02
Volume
338,276
Average Volume
620,147
Market Cap
263.4M
Market Cap / Employee
$5.23M
52wk Range
$2.32 - $6.07
Revenue
-
Gross Margin
0.72%
Dividend Yield
N/A
EPS
$0.98
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Puma Biotechnology Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PBYI+84.15%-44.95%-11.25%-61%
S&P+14.5%+93.32%+14.09%+386%

Puma Biotechnology Company Info

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$52.44M11.4%
Gross Profit$40.14M10.2%
Gross Margin76.54%-0.8%
Market Cap$170.26M8.3%
Market Cap / Employee$0.99M0.0%
Employees172-7.0%
Net Income$5.86M229.3%
EBITDA$9.40M1189.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$56.75M-15.5%
Accounts Receivable$25.91M-7.8%
Inventory8.6-5.1%

Liabilities

Q2 2025YOY Change
Long Term Debt$10.87M-77.4%
Short Term Debt$38.36M-24.0%

Ratios

Q2 2025YOY Change
Return On Assets24.23%19.9%
Return On Invested Capital-8.88%16.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$14.06M1296.4%
Operating Free Cash Flow$14.08M1271.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings5.375.003.853.50-80.37%
Price to Book1.762.111.581.75-43.16%
Price to Sales0.510.650.630.720.57%
Price to Tangible Book Value7.148.543.553.52-116.67%
Price to Free Cash Flow TTM3.723.884.743.89-17.85%
Enterprise Value to EBITDA4.617.6417.1513.10-94.00%
Free Cash Flow Yield26.9%25.8%21.1%25.7%21.73%
Return on Equity42.3%41.6%51.4%63.2%186.14%
Total Debt$86.37M$74.08M$61.71M$49.23M-50.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.